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Introduction
JNKs have been discovered as serine/threonine protein kinases 
stimulated by cycloheximide (Kyriakis et al., 1994), UV light 
(Dérijard et al., 1994), or IL-1 (interleukin-1; Kracht et al., 
1994).  Three  JNK  genes,  which  are  present  only  in  higher   
eukaryotes, encode up to 10 homologous isoforms designated 
“short” JNKs (Mr of 45–48 kD) or “long” JNKs (Mr of 54– 
57 kD; Gupta et al., 1996). Mice deficient in one JNK gene are 
viable, whereas double deficiency of JNK1 and JNK2 genes is 
embryonic lethal (Kuan et al., 1999). In mouse models of dis-
ease, JNKs play roles in diabetes, ischemia/reperfusion injury, 
rheumatoid arthritis, deafness, and tumor progression (Johnson 
and Nakamura, 2007).
Despite  their  widespread  activation  by  a  plethora  of   
inflammatory or environmental stimuli, including any form of 
stress, the number of identified JNK substrates or direct down-
stream effectors that may account for these in vivo phenotypes 
is still fairly small (Bogoyevitch and Kobe, 2006) and mainly 
comprises proteins involved in gene transcription (e.g., c-Jun 
and ATF-2), apoptosis (e.g., bcl2), insulin signaling (IRS-1), or 
neurodegeneration (e.g., Tau). JNK catalytic activity is stimulated 
by sequential phosphorylation through kinase cascades involv-
ing MAPKKKKs (e.g., germinal center kinase), MAPKKKs 
(e.g., TAK1 [TGF-–activated kinase 1] and MEKK1 [mitogen- 
activated  extracellular-regulated  kinase  kinase  kinase  1]),   
and MAPKKs (e.g., MKK4 and MKK7; Gaestel et al., 2009; 
Zhong et al., 2009). JNKs can also bind to these activators, their 
substrates (such as c-Jun), or to scaffolding proteins (such as 
JIP1–4 [JNK-interacting protein 1–4]), implying that an as yet 
unknown array of dynamically built signaling complexes recruits 
JNKs to precisely direct their manifold subcellular functions 
(Johnson and Nakamura, 2007; Weston and Davis, 2007).
Many of the stressors that activate JNK also affect forma-
tion of compositionally related cytoplasmic RNP (ribonucleo-
protein) granules, called processing bodies (P bodies) and stress 
granula (Anderson and Kedersha, 2009; Buchan and Parker, 2009). 
mRNPs contain messenger RNAs, which are enclosed by a pro-
tein coat of factors binding to the m
7G (N7-methylguanosine) 
cap structure elements, to AU (adenine uridine)-rich elements, or   
to the poly(A) tail. These proteins regulate association with poly-
ribosomes  and  active  translation,  or  they  promote  sequential 
C
ytokines and stress-inducing stimuli signal through 
c-Jun  N-terminal  kinase  (JNK)  using  a  diverse 
and  only  partially  defined  set  of  downstream 
effectors. In this paper, the decapping complex subunit 
DCP1a was identified as a novel JNK target. JNK phos-
phorylated DCP1a at residue S315 in vivo and in vitro 
and coimmunoprecipitated and colocalized with DCP1a 
in processing bodies (P bodies). Sustained JNK activation 
by several different inducers led to DCP1a dispersion from 
P  bodies,  whereas  IL-1  treatment  transiently  increased   
P body number. Inhibition of TAK1–JNK signaling also   
affected  the  number  and  size  of  P  bodies  and  the   
localization of DCP1a, Xrn1, and Edc4. Transcriptome 
analysis further identified a central role for DCP1a in IL-1– 
induced messenger ribonucleic acid (mRNA) expression. 
Phosphomimetic mutation of S315 stabilized IL-8 but not 
IB mRNA, whereas overexpressed DCP1a blocked IL-8 
transcription and suppressed p65 NF-B nuclear activity. 
Collectively, these data reveal DCP1a as a multifunctional 
regulator of mRNA expression and suggest a novel mech-
anism controlling the subcellular localization of DCP1a in 
response to stress or inflammatory stimuli.
c-Jun N-terminal kinase phosphorylates DCP1a  
to control formation of P bodies
Katharina Rzeczkowski,
1 Knut Beuerlein,
1 Helmut Müller,
1 Oliver Dittrich-Breiholz,
2 Heike Schneider,
2  
Daniela Kettner-Buhrow,
1 Helmut Holtmann,
2 and Michael Kracht
1
1Rudolf Buchheim Institute of Pharmacology, Justus Liebig University Giessen, 35392 Giessen, Germany
2Institute of Biochemistry, Hannover Medical School, 30623 Hannover, Germany
© 2011 Rzeczkowski et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the pub-
lication date (see http://www.rupress.org/terms). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, 
as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
YJCB • VOLUME 194 • NUMBER 4 • 2011   582
JNK, we cotransfected JNK, MEKK1-BFP, or a TAK1-TAB1 
fusion protein (Fig. 1 A; Sakurai et al., 2002). MEKK1-BFP 
and  TAK1-TAB1  strongly  activated  endogenous  JNK  as   
assessed by phosphorylation of the JNK substrate c-Jun, whereas 
expression of JNK alone had little effect on c-Jun phosphoryla-
tion (Fig. 1 B). There was no effect on the overall expression 
levels of GFP-DCP1a (Fig. 1 B). Cells expressing GFP-DCP1a 
and MEKK1 or TAK1-TAB1 showed a dramatic dispersion of 
P bodies to large structures, covering essentially major areas 
of the entire cytoplasm (Fig. 1 A, lanes 2 and 5). These struc-
tures correspond to ubiquitously distributed GFP-DCP1a in the   
cytoplasm, an effect that was also partially seen with trans-
fected JNK alone (Fig. 1 A, lane 3) but not with a catalytically 
inactive JNK2 mutant (Fig. 1 A, lane 4). In fact, the JNK mu-
tant colocalized exactly with GFP-DCP1a in P bodies (Fig. 1 A, 
lanes 4 and 7), implying that loss of enzymatic activity stabi-
lizes potential intracellular interactions of JNK with DCP1a in 
intact cells. Under conditions of maximal JNK activation (i.e., 
overexpression of JNK plus TAK1-TAB1 or of MEKK1-BFP), 
JNK also colocalized with GFP-DCP1a in the cytoplasm as   
evident from the appearance of overlapping fluorescence signals   
(Fig. 1 A, lanes 2 and 6). These data indicated that JNK activa-
tion is dynamically linked to P body formation and to the asso-
ciation of DCP1a with JNK.
JNK phosphorylates DCP1a at S315
In  the  experiments  shown  in  Fig.  1  B,  JNK  activation  by 
MEKK1  or  TAK1-TAB1  resulted  in  strong  mobility  shifts   
of  DCP1a  upon  SDS-PAGE.  These  shifts  are  indicative  of 
multisite  phosphorylation.  At  least  two  different  phosphory-
lation states (designated form 2 and form 3) were observed   
(Fig. 1 B). Form 2 was further converted to form 3 by co-
expression of TAK1-TAB1 with wild-type JNK2 but not with 
JNK2K55R (Fig. 1 B). Using this assay, mutational analysis of a 
total of 20 candidate proline-directed MAPK phosphorylation 
sites (Fig. S1 A) revealed S315 as a possible JNK target site in 
DCP1a because this mutant showed a conversion of form 2 back 
to form 1 upon TAK1-TAB1 transfection (Fig. S1 B). Moreover, 
JNK phosphorylated GST-DCP1a directly in vitro (Fig. 2 A).   
Phosphospecific antibodies against S315 confirmed that DCP1a 
is phosphorylated by JNK at this site in vitro (Fig. 2 B) as well 
as in cells overexpressing JNK activators (Fig. 2 C). In con-
trast, p38 MAPK did not phosphorylate S315 of DCP1a in vitro   
(unpublished data).
JNK interacts with DCP1a and mediates 
DCP1a phosphorylation at S315 in 
response to cytokines and stressors
The kinetics of JNK activation varies depending on the stimu-
lus. Proinflammatory stimuli like IL-1 cause transient JNK 
activation, whereas osmotic or translational stress by sorbitol 
or anisomycin, respectively, causes long-lasting and strong 
activation of JNK and p38 MAPK (Fig. 3 A). IL-1 induced 
a more modest and transient increase in DCP1a phosphory-
lation, whereas sorbitol and anisomycin induced a rapid and 
quantitative shift of endogenous DCP1a to form 2 as well 
as  phosphorylation  at  S315  (Fig.  3  A).  Inhibition  of  JNK 
deadenylation  (Yamashita  et  al.,  2005),  decapping  (Sheth 
and Parker, 2003), and subsequent decay of mRNAs (Cougot 
et al., 2004; Eulalio et al., 2007a; Buchan and Parker, 2009).   
P bodies and stress granula share protein components, such as 
the 5–3 exonuclease Xrn1 (Kedersha et al., 2005). P bodies 
are distinguished by various subunits of the decapping complex, 
including DCP2 (Beelman et al., 1996) and DCP1a (Lykke- 
Andersen,  2002;  Fenger-Grøn  et  al.,  2005)  and  are  consid-
ered as primary sites of mRNA degradation. However, dispersed   
P  body  proteins  are  still  fully  competent  for  mRNA  decay   
(Eulalio et al., 2007b). Hence, P bodies may fulfill additional func-
tions, such as transient mRNA storage or sequestration of RNA- 
metabolizing enzymes (Franks and Lykke-Andersen, 2008).
P bodies become detectable when levels of nontranslat-
able mRNA increase, and they disassemble upon depletion of 
cytoplasmic pools of mRNA (Teixeira et al., 2005; Eulalio et al., 
2007b). The signals that regulate aggregation or disaggrega-
tion of P bodies in mammalian cells are not well understood 
(Franks and Lykke-Andersen, 2008; Ohn et al., 2008). Recently, 
phosphorylation of DCP2 by the yeast MAPKKKK Ste20 was 
shown to affect the decay of distinct mRNAs, providing the   
first example of signal-dependent regulation of the decapping 
machinery (Yoon et al., 2010).
In  mammalian  cells,  a  TAK1–JNK  pathway  integrates 
signals from conditions as divergent as osmotic stress (Huangfu 
et al., 2006) or inflammatory cytokine signaling (Shim et al., 
2005). TAK1, the regulatory subunits TAB1–3 (TAK1-binding 
protein 1–3), and JNK are core parts of a signaling module that 
regulates transcription, mRNA stability, and translation of IL-1 
target genes (Krause et al., 1998; Holtmann et al., 1999, 2001; 
Winzen et al., 1999, 2007; Hoffmann et al., 2005; Wolter et al., 
2008; Dhamija et al., 2010). TAK1 also activates the transcrip-
tion factor NF-B, which cooperates with JNK to activate genes 
at the level of chromatin (Holtmann et al., 2001; Hoffmann   
et al., 2005; Thiefes et al., 2005; Wolter et al., 2008).
IL-1–mediated gene expression occurs within 30–60 min 
and is usually terminated after a few hours. The kinetics and 
amplitude of mRNA synthesis, degradation, and translation 
are regulated by multiple mechanisms that operate in parallel   
within a signaling network, which is still incompletely under-
stood (Hoffmann et al., 2002; Gaestel et al., 2009; Weber   
et al., 2010).
Here,  we  report  that  JNK-mediated  phosphorylation  of 
DCP1a at S315 controls subcellular localization of DCP1a as well 
as P body formation during translational stress but also in re-
sponse to IL-1. We also demonstrate an additional role of DCP1a 
in IL-1– and NF-B–dependent transcriptional regulation.
Results
Ectopic activation of the JNK pathway 
affects localization and modification  
of DCP1a
We transiently transfected GFP-DCP1a, which essentially be-
haves like endogenous DCP1a as a marker for P bodies (Sheth 
and Parker, 2003; Tritschler et al., 2009). To analyze the cel-
lular localization of GFP-DCP1a under conditions of activated 583 JNK interacts with and phosphorylates DCP1a • Rzeczkowski et al.
activator of several protein kinases, including JNK and p38 
MAPK (Shim et al., 2005; Thiefes et al., 2005), this result sug-
gested that DCP1a is subject to multiple modifications exerted 
by several enzymes.
Here, we focused on JNK, which clearly is a direct S315 
kinase. To study the interaction of JNK with DCP1a, we frac-
tionated cell extracts into soluble and particular fractions as   
described for yeast (Teixeira et al., 2005). The particular fraction   
(P2) is enriched in P bodies (Fig. S2), whereas the soluble frac-
tion (S2) contains cytosolic DCP1a (Fig. 3 D). DCP1a copre-
cipitated with endogenous JNK (Fig. 3 D). This interaction was 
independent of stimulation and occurred in S2 and P2 fractions 
(Fig. 3 D). We did not find coimmunoprecipitation with Edc4 or 
by SP60025, but not inhibition of p38 MAPK by SB203580,   
inhibited IL-1– or anisomycin-induced DCP1a phosphorylation   
by 100, whereas sorbitol-induced phosphorylation was inhib-
ited by 30–40% (Fig. 3 B). SP600125 did not strongly affect 
the mobility shift of DCP1a upon SDS-PAGE, indicating that 
DCP1a undergoes additional modifications at other amino   
acids (Fig. 3 B). One of the modified residues is S319, which is   
also phosphorylated by activated JNK + TAK1-TAB1 (Fig. S1   
and not depicted). A specific inhibitor of TAK1, 5Z-7-oxo-
zeaenol (Ninomiya-Tsuji et al., 2003), almost completely pre-
vented both phosphorylation of DCP1a at S315 as well as   
the mobility shifts upon SDS-PAGE in response to IL-1, an-
isomycin, and sorbitol (Fig. 3 C). As TAK1 is an upstream 
Figure 1.  JNK activators affect localization of DCP1a to P bodies. (A) HEK293IL-1R cells were transfected with vectors encoding GFP-DCP1a together with 
JNK activators (MEKK1 or a TAK1-TAB1 fusion protein) or with JNK wild type or a catalytically inactive mutant (JNK2K55R). Colocalization of GFP-DCP1a 
(green) with JNK (red) was analyzed by fluorescence microscopy. The fraction of transfected cells exhibiting a phenotype identical to that shown in the 
representative image was determined by scoring ≥50 cells from three to four independent transfections. Bar, 10 µm. IF, indirect immunofluorescence.   
(B) HEK293IL-1R cells were transfected in parallel cultures, and modifications of GFP-DCP1a were analyzed by mobility shifts (labeled 1–3) upon SDS-PAGE 
and subsequent Western blot analysis. Equal expression and activity of cotransfected constructs were validated by anti-JNK, anti-GFP, anti-TAK1, and 
antiphospho–c-Jun (P-c-Jun) antibodies. Proteins from the same samples were separated on three gels and transferred to three membranes (M1–M3), which 
were probed with the indicated antibodies. Ponceau staining or hybridization with antiactin or antitubulin antibodies is shown to indicate equal protein 
loading. IB, immunoblot; n.s., nonspecifically detected protein band that served as a loading control.JCB • VOLUME 194 • NUMBER 4 • 2011   584
phosphorylated DCP1a, whereas cytosolic Xrn1 showed fewer 
overlapping fluorescence signals (Fig. 4 B, lane 2). Upon IL-1 
stimulation, Edc4 colocalized with DCP1a and phospho-DCP1a 
in all P bodies (Fig. 4 B, lane 2). SP600125 strongly inhibited 
the IL-1–induced increase in P body number as well as DCP1a 
phosphorylation (Fig. 4 B, lanes 4 and 5). Thus, in the IL-1 path-
way, JNK-mediated DCP1a phosphorylation is strictly associ-
ated with P body assembly. Anisomycin caused strong DCP1a 
phosphorylation and disruption of P body structures as judged 
from  the  dispersed  localization  of  DCP1a,  Xrn1,  and  Edc4   
(Fig. 4 B, lanes 6 and 7). In line with Western blot analyses of 
total  cell  extracts  (Fig.  3  B),  SP600125  blocked  anisomycin- 
induced DCP1a phosphorylation (Fig. 4 B, lanes 8 and 9).   
However, this did not restore P body structures (Fig. 4 B, lanes 8 
and 9). Similar to anisomycin, sorbitol treatment caused strong 
DCP1a phosphorylation and P body disassembly (Fig. 4 B,   
lanes 10 and 11). However, in contrast to anisomycin, SP600125 
only weakly affected total cellular DCP1a phosphorylation, but   
it  significantly  restored  the  formation  of  P  body–like  struc-
tures containing Xrn1 and Edc4 (Fig. 4 B, lanes 12 and 13).   
Xrn1 (unpublished data). These data indicated that JNKs form a 
stable complex with DCP1a and interact with specific subunits 
of the decapping complex.
JNK activation affects localization of 
DCP1a, Edc4, and Xrn1 to P bodies
We then studied the localization of P body components under 
conditions of JNK activation or JNK inhibition in human cells. 
Sorbitol and anisomycin treatment led to complete disappear-
ance of DCP1a from P bodies and to its redistribution to the 
cytoplasm within 1–2 h (Fig. 4, A and B), resembling the effects   
of overexpressed JNK, TAK1-TAB1, or MEKK1 as shown in   
Fig. 1 A. In contrast, IL-1 treatment transiently increased the 
number of P bodies by 75% after 1 h of stimulation (Fig. 4,   
A–C).  In  untreated  cells,  there  was  very  little  DCP1a  phos-
phorylation and localization of DCP1a in P bodies merged with 
Edc4 and Xrn1 as expected (Fig. 4 B, lane 1). After 1 h of IL-1   
stimulation,  phosphorylation  of  DCP1a  in  the  cytoplasm,  but 
much more pronounced in all P bodies, was strongly induced 
(Fig.  4  B,  lane  2).  P  body–associated  Xrn1  colocalized  with 
Figure 2.  JNK phosphorylates DCP1a at S315. (A) HEK293IL-1R cells were stimulated for 60 min with 0.5 M sorbitol or were left untreated. JNK was 
immunoprecipitated from cell extracts, and immune complex protein kinase assays were performed by addition of GST–c-Jun1–135 or GST-DCP1a and   
radioactive ATP. (top) Reaction mixtures were separated by SDS-PAGE and visualized by autoradiography. Equal loading of GST–c-Jun1–135 or GST-DCP1a 
substrates was confirmed by Coomassie brilliant blue (CBB) staining of gels. exp., exposure. (B) HEK293IL-1R cells were transfected with HA-JNK2, GFP-
DCP1a, or GFP-DCP1aS315A. 24 h later, HA-JNK2–transfected cells were stimulated for 60 min with 0.5 M sorbitol to activate JNK or were left untreated. 
Lysates were prepared, and JNK or GFP-DCP1a proteins were immunoprecipitated and mixed. In vitro kinase assays were started by addition of ATP and 
analyzed by immunoblotting for phosphorylation of DCP1a at S315. Proteins in lysates and immunoprecipitates were analyzed by the indicated antibodies. 
(C) HEK293IL-1R cells were transfected as described in the legend for Fig. 1 B, but GFP-DCP1a constructs were omitted. Phosphorylation of endogenous 
DCP1a was analyzed by SDS-PAGE/immunoblotting using P(S315)-DCP1a and DCP1a antibodies, respectively. Black lines indicate that intervening lanes 
have been spliced out. IB, immunoblot; IP, immunoprecipitation.585 JNK interacts with and phosphorylates DCP1a • Rzeczkowski et al.
Anisomycin inhibits translation at the elongation step (Tscherne 
and  Pestka,  1975)  similar  to  cycloheximide,  which  prevents 
formation of RNP particles by lowering the cytoplasmic pool 
of nontranslatable RNA (Cougot et al., 2004). Therefore, these 
results suggested that in the anisomycin pathway, RNA deple-
tion is likely to override phosphorylation-dependent control by 
DCP1a, whereas in the IL-1 and sorbitol pathways, JNK con-
trols P body formation through DCP1a phosphorylation. In sup-
port for this conclusion, we found that DCP1a phosphorylation 
was strongly reduced in murine embryonic fibroblasts (MEFs) 
lacking JNK but not p38 MAPK (Fig. S3 A). Moreover, unlike 
wild-type  or  p38-deficient  MEFs,  cells  lacking  JNK1/2  were 
largely devoid of P bodies (Fig. S3 B). These data support a role 
of JNK, but not p38 MAPK, in P body formation, in line with 
a lack of SB203580 to affect the sorbitol-induced reduction of   
P bodies (Fig. S3 C) in human cells.
Mutation of S315 in DCP1a affects 
localization but not decapping activity
To  establish  a  direct  link  between  DCP1a  phosphorylation,   
localization, and function, we transiently expressed DCP1a ver-
sions carrying inactivating (S315A) or phosphomimetic (S315D) 
mutants in HEK293IL-1R cells. GFP-DCP2 or a C-terminal 
truncation  mutant  of  GFP-DCP1a,  GFP-DCP1a515–582,  was   
expressed in parallel (Fig. 5). Amino acids 515–582 of DCP1a 
were recently shown to be required for DCP1a trimerization, 
interaction  with  other  decapping  factors,  and  decapping  en-
hancer activity (Tritschler et al., 2009). In line with the latter 
study,  immunoprecipitated  GFP-DCP2  was  active,  whereas 
GFP-DCP1a515–582 had hardly any detectable decapping activ-
ity (Fig. 5, left, lanes 2 and 6). Weak endogenous decapping 
activity was associated with immunoprecipitated GFP-DCP1a, 
which was, however, independent from mutations of S315 (Fig. 5,   
left, lanes 3–5). Thus, phosphorylation of DCP1a at S315 is un-
likely to affect global cellular decapping activity.
To reveal a direct link between DCP1a phosphorylation 
and localization, we generated stable cell lines expressing com-
parable amounts of inactivating and phosphomimetic mutants 
of  S315  (Fig.  6 A).  Compared  with  wild-type  GFP-DCP1a 
(8.6  ±  0.5  P  bodies  per  cell;  Fig.  6  B),  mutation  of  S315   
to alanine increased the number (12 ± 0.2 P bodies per cell; 
Fig. 6 B) and size of P bodies (Fig. 6 C, lane 2), whereas mu-
tation to asparagine strongly reduced P body number (3.4 ± 
1.1 P bodies per cell; Fig. 6 B) and led to cytosolic redistribu-
tion of GFP-DCP1a (Fig. 6 C, lane 3). In line with the results 
shown in Fig. 4 B, the distribution of Xrn1 and Edc4 followed 
the  localization  of  GFP-DCP1a  and  its  mutants,  suggest-
ing that S315 affects P body formation (Fig. 6 C, lanes 1–3). 
JNK was detected throughout the cell, including the nucleus, 
as expected (Fig. 6 C). However, JNK was also detected in 
RNP-like structures in which it colocalized with GFP-DCP1a   
(Fig.  6  C,  bottom  insets).  The  S315A  mutation  stabilized   
colocalization of JNK with GFP-DCP1a in P body structures   
(Fig. 6 C). A dispersion of P body structures was also seen with 
the C-terminal truncation mutant GFP-DCP1a515–582 (Fig. 6,   
B and C), which was consistant with a recent study (Tritschler 
et al., 2009). Compared with the GFP-DCP1aS315D mutant, more 
Edc4- and Xrn1-containing RNPs remained detectable in cells 
expressing the GFP-DCP1a515–582 mutant (Fig. 6 C). Collec-
tively, the data shown in Fig. 6, therefore, suggest that at the 
protein level, DCP1a localization is regulated by at least two 
mechanisms, one involving JNK-mediated phosphorylation at 
S315 and the other involving oligomerization and interaction of 
its C terminus with other components of mRNPs, such as Edc4 
and DCP2 (Tritschler et al., 2009).
Ectopic expression of DCP1a mutants 
affect mRNA levels of IL-1–induced genes
The clear differences in subcellular localization of stably trans-
fected  GFP-DCP1a  mutants  suggested  that  these  cells  were   
useful for assessing the relevance of DCP1a phosphorylation for 
IL-1–mediated gene expression. In two independent experiments, 
we analyzed genome-wide mRNA expression after 3 h of IL-1 
treatment by DNA microarray experiments. Out of 15,713 anno-
tated genes, 10,743 mRNAs were expressed at detectable levels. 
42 mRNAs were induced by IL-1 by at least twofold in parental 
HEK293IL-1R cells in both independent experiments (Fig. S4). 
Of those, in GFP-DCP1a–expressing cells, 28 genes (67%) and, 
in GFP-DCP1aS315D– or in GFP-DCP1a515–582–expressing cells, 
11 genes (26%) were still inducible by IL-1 by at least 1.5-fold, 
whereas in the GFP-DCP1aS315A mutant cells, the entire IL-1 gene 
response was impaired (Fig. S4). In untreated cells, 15–32 genes 
were up-regulated, and 252–360 genes were down-regulated in 
the four cell lines, indicating that GFP-DCP1a overexpression 
exerts minor effects on up-regulation of genes but negatively 
affects 2.3–3.4% of all detectable transcripts. However, there 
were little differences between the various mutants and wild-type 
GFP-DCP1a on this set of transcripts (unpublished data).
We focused on IL-8, whose transcriptional and posttran-
scriptional regulation we have investigated previously in great 
detail (Holtmann et al., 2001; Winzen et al., 2007; Dhamija   
et al., 2010). As expected, IL-1 induced strong IL-8 secretion 
in parental HEK293IL-1R cells (Fig. 7 A), whereas the transla-
tional inhibitors anisomycin and sorbitol failed to induce IL-8   
secretion  (Fig.  7 A).  Compared  with  parental  cells,  ectopic 
expression of wild-type GFP-DCP1a did not affect IL-8 se-
cretion, whereas expression of either GFP-DCP1aS315D or GFP-
DCP1a515–582 strongly suppressed IL-1–induced IL-8 protein 
secretion. Inducible IL-8 secretion was completely absent in 
GFP-DCP1aS315A–expressing cells (Fig. 7 B). In line with this 
result and with the microarray data, GFP-DCP1aS315D or GFP-
DCP1a515–582  also  strongly  suppressed,  but  not  completely 
abolished, IL-8 mRNA expression (Fig. 7 C). A similar pattern 
of inhibition by the DCP1a mutants was seen for IB mRNA, 
another IL-1–inducible transcript (Fig. 7 D). To assess the rele-
vance of DCP1a for IL-8 and IB mRNA stability, we induced 
mRNA synthesis by IL-1 treatment for 1 h, and then followed 
mRNA decay over time after the addition of actinomycin D 
(Fig. 7 E). About 40–50% of IL-8 mRNA and 90% of IB 
mRNA were degraded after 100 min (Fig. 7 E). IL-8 mRNA 
decay was almost completely impaired by the GFP-DCP1aS315D 
mutant but not by the other GFP-DCP1a mutants or wild-type 
GFP-DCP1a (Fig. 7 E). Moreover, the stabilizing effect of GFP-
DCP1aS315D was transcript specific, as none of the GFP-DCP1a JCB • VOLUME 194 • NUMBER 4 • 2011   586
Figure  3.  JNK interacts with DCP1a and controls phosphorylation of DCP1a at S315 in response to stress stimuli and IL-1.  (A)  HEK293IL-1R  cells  were  left  untreated 
(2) or were treated for the indicated times with 10 ng/ml IL-1, 10 µg/ml anisomycin, 0.2% DMSO, or 0.5 M sorbitol. Lysates were immunoblotted, and phos-
phorylation of DCP1a, JNK, p38 MAPK, and c-Jun was analyzed by the indicated antibodies. (B and C) Cells were left untreated or were treated as indicated for   
30 min with solvent (0.05% DMSO) or 20 µM SP600125, 2 µM SB203580, or 1 µM 5Z-7-oxozeaenol to inhibit JNK, p38 MAPK, or TAK1, respectively. 
Thereafter, cells were treated with IL-1, anisomycin, or sorbitol for 1 h, and expression and phosphorylation of DCP1a and phosphorylation of p55 JNK 
were analyzed as in A. In B, proteins from IL-1– and anisomycin-treated samples were separated side by side on three separate gels and transferred to 
three membranes (M1–M3), which were probed with the indicated antibodies. Loading controls for M1–M3 are shown by antiactin antibodies or Ponceau 
or Coomassie brilliant blue (CBB) staining of membranes. Proteins from sorbitol-treated samples were loaded twice on the same gel and transferred to the 
same membrane. One half of the membrane (M4a) was probed with antiphospho-DCP1a (P-DCP1a), DCP1a, and actin antibodies, and the other half 
(M4b) was probed with antiphospho-JNK (P-JNK) and antiactin antibodies. (D) HEK293IL-1R cells were treated for 1 h with IL-1, anisomycin, or sorbitol. 
Then cytosolic (S2) and P body–enriched particular (P2) fractions were prepared as previously described in Teixeira et al. (2005). Immunoprecipitations 587 JNK interacts with and phosphorylates DCP1a • Rzeczkowski et al.
Collectively, the results shown in Fig. 5, Fig. 6, and Fig. 7 
suggested  that  phosphorylation  of  DCP1a  at  S315  regulates 
DCP1a localization to P bodies but does not affect total cellular 
versions affected the rapid decay of IB (Fig. 7 E). It should 
be noted that basal mRNA steady-state levels for IB and IL-8 
were similar in all cell lines (Fig. 7, C and D).
were performed using anti-JNK or -IgG antibodies and analyzed for coprecipitation of DCP1a. Blots were also probed for p54 JNK. Proteins from the same 
lysates were separated on two gels and transferred to two membranes (M1 and M2). M1 was hybridized with DCP1a and antiactin antibodies, and M2 
was hybridized with anti-JNK and antiactin antibodies. Coomassie brilliant blue stains for M1 and M2 are shown to indicate equal protein loading of S2 
and P2 fractions. Black lines indicate that intervening lanes have been spliced out. rel., relative; IB, immunoblot; IP, immunoprecipitation; n.s., nonspecifi-
cally detected protein band that served as a loading control.
 
Figure 4.  JNK-mediated phosphorylation of DCP1a at S315 controls DCP1a localization and P body number. (A) HEK293IL-1R cells were left untreated 
(2) or were stimulated for the indicated times with 10 ng/ml IL-1, 10 µg/ml anisomycin, or 0.5 M sorbitol, and DCP1a-containing P bodies (green) were 
analyzed by fluorescence microscopy. (B) Cells were stimulated for 1 and 2 h as in A. In addition, cells were pretreated for 30 min with 20 µM SP600125 
as indicated. Localization of DCP1a, P(S315)-DCP1a, Edc4, and Xrn1 in P bodies was analyzed by double immunofluorescence as indicated. IF-control 
indicates samples from which first antibodies were omitted. Bars, 10 µm. IF, indirect immunofluorescence. (C) Statistics of P body number per cell under 
conditions of B. Depicted is the mean P body number per cell ± SEM counted in ≥50 cells taken from two time points. Asterisks indicate significant changes 
for pairwise comparisons.JCB • VOLUME 194 • NUMBER 4 • 2011   588
protein levels in the absence or presence of GFP-DCP1a. Based 
on this analysis, GFP-DCP1a reduces GAL4-p65 activity by 
58–76% (Fig. 8 B). In this assay, a GAL4-DCP1a fusion pro-
tein had very low transcriptional activity on its own (0.043 ± 
0.0015 relative light units [RLUs]; Fig 8 C, lane 4) compared 
with background levels (0.00078 ± 0.00037 RLUs; Fig. 8 C,   
lane 2). This low activity was completely abolished by deleting 
amino  acids  125–377  (unpublished  data),  confirming  previ-
ous observations (Bai et al., 2002). In comparison, GAL4-p65   
NF-B was >10,000 times more active when transfected in paral-
lel under identical conditions (54.82 ± 19.17 RLUs; Fig. 8 C, 
lane 8). The inhibitory effect of GFP-DCP1a, as shown in 
Fig. 8 B, was enhanced when DCP1a was tethered together 
with GAL4-p65 to the GAL4 promoter using GAL4-DCP1a 
fusion proteins (Fig. 8 C). The suppression of p65 activity 
by  GFP-DCP1a  or  GAL4-DCP1a  was  independent  from 
S315 but was stronger with GFP-DCP1a515–582 (Fig. 8 B)   
or GAL4-DCP1a515–582 (Fig. 8 C), respectively, suggesting 
that it is under negative control of the C-terminal trimeriza-
tion domain of DCP1a. Inhibition of p65 may involve direct   
interaction of DCP1a and p65 NF-B in the nucleus because 
both proteins could be coimmunoprecipitated using antibod-
ies against p65 or DCP1a. (Fig. 8 D), and we found a small   
amount of endogenous DCP1a in the nucleus (Fig. 8, E and F). 
The data shown in Fig. 8 can be reconciled with a transcriptional 
corepressor function of DCP1a for p65 NF-B but may also 
decapping activity. Rather, phosphorylation appears to contrib-
ute to mRNA stabilization of selective IL-1 target genes, such 
as IL-8.
DCP1a suppresses IL-1–induced 
transcription by negatively regulating  
p65 NF-B
Given the strong dominant-negative phenotype of stably ex-
pressed  GFP-DCP1a  mutants  on  IL-1–induced  IL-8  mRNA 
steady-state levels, we also investigated their role in IL-8 tran-
scription using promoter reporter gene assays. There was an un-
expected strong suppression of inducible IL-8 transcription that 
mirrored the extent of inhibition on IL-8 mRNA levels by the 
GFP-DCP1aS315A, GFP-DCP1aS315D, or GFP-DCP1a515–582 mu-
tants in the same cell lines (Fig. 8 A). p65 NF-B is the major 
transcriptional regulator of IL-1–induced genes, including IL-8 
(Hoffmann et al., 2005; Wolter et al., 2008; Weber et al., 2010). 
To get further insight into the underlying mechanisms of DCP1a-
dependent transcriptional inhibition, we fused p65 or DCP1a to 
the DNA-binding domain of the yeast transcription factor GAL4 
to analyze their effects on transcriptional activity in a mamma-
lian one-hybrid system using a luciferase reporter driven by five   
GAL4 binding sites. Coexpression of GFP-DCP1a wild type or its 
mutants significantly suppressed GAL4-p65–driven transcrip-
tion (Fig. 8 B). To assess the relative inhibitory effects of GFP-
DCP1a, we normalized the GAL4-p65 activity to GAL4-p65 
Figure 5.  Phosphorylation at S315 does not affect cellular decapping activity. HEK293IL-1R cells were transiently transfected with expression vectors en-
coding GFP-DCP2, wild-type GFP-DCP1a, inactivating (GFP-DCP1aS315A), or phosphomimetic (GFP-DCP1aS315D) mutants or a C-terminal deletion mutant of 
GFP-DCP1a (515–582). 24 h later, cells were lysed, and DCP2 or DCP1a were immunoprecipitated using anti-GFP antibodies or IgG as a control. Three 
fourths of the immunoprecipitates were incubated with a 
32P cap–labeled luciferase mRNA (
32P-luc. mRNA). After 30 min at 30°C, reactions were stopped, 
and reaction mixtures were separated by thin layer chromatography. The luciferase mRNA substrate and the 
32P-labeled m
7GDP cap structures that were 
hydrolyzed by exogenous DCP2 or by decapping activity associated with DCP1a immunoprecipitates were visualized by autoradiography. 
32P-labeled 
m
7GTP indicates a reaction product that was cleaved unspecifically. The correct size of m
7GDP was verified by nonradioactive standards run in parallel (not 
depicted). Lysates and one fourth of the immunoprecipitates were analyzed for equal expression and immunoprecipitation by anti-GFP antibodies. Shown 
is one representative out of three experiments. IP, immunoprecipitation.589 JNK interacts with and phosphorylates DCP1a • Rzeczkowski et al.
in vitro, establishing the first example of JNK targeting an RNA- 
decapping pathway protein directly. The sequence surrounding 
S315, PLSP, represents a consensus MAPK phosphorylation 
motif (Bogoyevitch and Kobe, 2006). Experiments using inhib-
itors for JNK (SP600125), p38 MAPK (SB203580), extracellu-
lar-regulated kinase (PD98059; unpublished data), and TAK1 
(5Z-7-oxozeaenol) as well as investigations of kinase-deficient 
embryonic fibroblasts indicated that during translational stress 
or IL-1 signaling, S315 is specifically targeted by the TAK1–JNK 
pathway. The TAK1-TAB1 fusion protein and MEKK1 caused 
mobility shifts and phosphorylation of DCP1a (Fig. 1 B and 
Fig. 2 C). However, we consider it unlikely that TAK1-TAB1 
be explained by DCP1a affecting mRNA steady-state levels   
of other nuclear factors that are required for full p65 NF-B– 
dependent transactivation.
Discussion
JNKs  have  been  implicated  in  AU-rich  element-mediated 
mRNA stabilization in T cells (Chen et al., 2000), alveolar epi-
thelial cells (Korhonen et al., 2007), and mast cells (Ming et al., 
1998), but in general, their role in mRNA decay pathways and 
in mRNA translation has been elusive. In this study, we found 
that JNK phosphorylated DCP1a at S315 in intact cells and   
Figure 6.  Phosphorylation at S315 affects number and size of DCP1a-containing P bodies. HEK293IL-1R cells were stably transfected with wild-type GFP-
DCP1a (wt), inactivating (GFP-DCP1aS315A), or phosphomimetic (GFP-DCP1aS315D) mutants or a C-terminal deletion mutant of GFP-DCP1a (515–582).   
(A) All mutants were expressed to similar amounts as assessed by immunoblotting. (B) Quantification of P bodies from stable cell lines described in A. 
Depicted is the mean GFP-DCP1a–positive P body number per cell ± SEM counted in ≥200 cells taken from two independent stable transfections. P-values 
indicate significant changes compared with GFP-DCP1a wild-type cells. (C) Colocalization of endogenous Xrn1, (top left, red), Edc4 (top right, red), or 
JNK (bottom, red) with stably expressed GFP-DCP1a (green) was analyzed by fluorescence microscopy. Boxes and insets show enlarged views of single 
P bodies that contain JNK. IF-control indicates samples from which the first antibodies were omitted. Bars, 10 µm. IF, indirect immunofluorescence; IB,   
immunoblotting. Black lines indicate that intervening lanes have been spliced out.JCB • VOLUME 194 • NUMBER 4 • 2011   590
Xrn 1. However, JNKs were also required for P body forma-
tion, as JNK inhibitors blocked the IL-1–induced P body in-
crease (Fig. 4), and P bodies were diminished in JNK-deficient 
cells (Fig. S3). It should be noted that biochemical fractionation   
(Fig. 3) but also colocalization experiments (Fig. 1 and Fig. 6) 
suggested that JNKs are permanently associated with DCP1a.   
In this way, JNKs can regulate multiple aspects of DCP1a func-
tion within the cytoplasm, in P bodies or within other cellular 
compartments by signal-mediated phosphorylation. In conjunc-
tion  with  previous  findings  (Franks  and  Lykke-Andersen, 
2008), our data now suggest three levels of control of DCP1a   
localization:  (1)  the  abundance  of  nontranslatable  RNAs  in 
the cytoplasm (Teixeira et al., 2005), (2) C terminus–mediated 
oligomerization and interaction with other P body components   
(Fig. 6; Tritschler et al., 2009), and (3) JNK-mediated phos-
phorylation at S315, which serves as a reversible molecular 
switch  to  dynamically  control  localization  of  DCP1a  and   
P body formation in different biological situations.
We followed the latter hypothesis, examining conditions 
representing either strong JNK activation and translational arrest 
(e.g., anisomycin and sorbitol treatment) or transient JNK acti-
vation and highly inducible gene expression (e.g., IL-1 treatment). 
or  MEKK1  directly  phosphorylate  the  PLSP  motif  within 
DCP1a even though the TAK1 inhibitor prevents DCP1a modi-
fications (Fig. 3 C). Rather, TAK1-TAB1 and MEKK1 indi-
rectly alter phosphorylation of DCP1a because they activate 
MAPKs, in particular JNK, via MAPKKs. Our results do not 
exclude the possibility that in other conditions, additional pro-
line-directed protein kinases may phosphorylate S315 or other 
residues in DCP1a. In fact, the strong mobility shifts of cellular 
DCP1a (Fig. 1, Fig. 2, and Fig. 3) and remaining radioactive 
phosphorylation  of  GST-DCP1aS315A  (not  depicted)  indicate 
further modifications of DCP1a. Future studies are required to 
work out all enzymes and the resulting posttranslational modifi-
cations that target DCP1a.
The starting point of this study was the observation that 
strong upstream activators of JNK promoted drastic changes 
in P bodies as detected using DCP1a as a marker. Moreover, 
JNK colocalized and coimmunoprecipitated with endogenous 
DCP1a. As most evident from the phenotype of a phospho-
mimetic mutation (S315D), phosphorylation of DCP1a at S315 
by JNK regulates the release of DCP1a from P bodies. This 
was paralleled by disintegration of P bodies as evident from the 
cytosolic redistribution of two other P body markers, Edc4 and 
Figure 7.  Phosphomimetic mutants of DCP1a at S315 affect IL-1–induced IL-8 expression and mRNA stability. (A and B) HEK293IL-1R cells (A) or stably 
transfected cell lines (B) as described in Fig. 6 were left untreated (2) or were treated for 8 h with 10 ng/ml IL-1, 10 µg/ml anisomycin, or 0.5 M 
sorbitol. IL-8 protein secreted in the cell culture supernatant was determined by ELISA and normalized for cell number according to total protein content 
of harvested cells. Shown is the mean IL-8 amount ± SEM from two independent experiments. The minus sign indicates samples from untreated cells.   
(C) HEK293IL-1R cells (parental) or stable cell lines as described in Fig. 6 were stimulated for the indicated times with 10 ng/ml IL-1, and IL-8 mRNA 
expression was determined by quantitative RT-PCR. Shown is the mean fold increase ± SEM compared with unstimulated GFP-DCP1a (wt, wild type)– 
expressing cells from duplicate measurements of two independent experiments. (D) Cells as in C were stimulated for 1 h, and IB mRNA expression was 
analyzed and quantified as in C. (E) HEK293IL-1R cells (parental, red) or stable cell lines (GFP-DCP1a, blue; GFP-DCP1aS315A, green; GFP-DCP1aS315D, 
purple; GFP-DCP1a515–582, light blue) were treated for 1 h with 10 ng/ml IL-1 to induce mRNA transcription. Thereafter, 5 µg/ml actinomycin D was 
added, and total RNA was isolated after the indicated times and analyzed for the expression of IL-8 or IB mRNA by quantitative RT-PCR. Shown are 
relative mRNA levels ± SEM from duplicate measurements of three independent experiments.591 JNK interacts with and phosphorylates DCP1a • Rzeczkowski et al.
Figure 8.  DCP1a inhibits IL-8 transcription and acts as a transcriptional suppressor for p65 NF-B. (A) Stable cell lines as described in Fig. 6 and Fig. 7 
were transiently transfected with the IL-8 promoter luciferase (luc.) and SV40–-galactosidase (-gal.) constructs. After 24 h, cells were stimulated for 4 h 
with 10 µg/ml IL-1 and lysed, and luciferase activity was determined. Shown is the mean luciferase activity ± SEM normalized for -galactosidase activity 
from duplicate measurements of two independent experiments. (B) HEK293IL-1R cells were left untransfected or were transfected with 3 µg GFP-DCP1a, 
empty vector, or a GAL4 expression construct and 1 µg GAL4-p65 in the indicated combinations. 1 µg luciferase vector containing five GAL4 binding 
sites (pFR-luciferase) and 1 µg SV40–-galactosidase were cotransfected. 24 h later, cells were lysed, and luciferase activity was determined. Lysates were 
examined for expression of GAL4 and GFP fusion proteins using anti-GAL4 or anti-GFP antibodies. Blots were probed with antiactin antibodies to confirm 
equal loading. Shown is the mean luciferase activity (RLU) ± SEM from six independent experiments. Numbers in percentages display relative luciferase 
activity of GAL4-p65 in the absence or presence of GFP-DCP1a constructs. These values were also normalized to GAL4-p65 expression levels to account 
for differences in GAL4-p65 amounts as in the particular Western blot shown. (C) HEK293IL-1R cells were transfected in the indicated combinations as in B 
but with GAL4-DCP1a constructs instead of GFP-DCP1a. Lysates were also examined for equal expression of GAL4 fusion proteins using GAL4 antibodies.   
A nonspecifically detected protein band served as a loading control. Shown is the mean luciferase activity (RLU) ± SEM from four independent experiments. 
Numbers in percentages display relative luciferase activity of GAL4-p65 in the absence or presence of GAL4-DCP1a constructs. (D) HEK293IL-1R cells 
were transfected with expression vectors encoding epitope-tagged p65 NF-B or GFP-DCP1a. 24 h later, cells were lysed, and immunoprecipitations were 
performed using anti-p65, anti-DCP1a, or IgG control antibodies in the indicated combinations. Lysates and immunoprecipitates were analyzed by Western 
blotting for overexpressed p65 and DCP1a proteins as indicated. (E) HEK293IL-1R cells were treated for 1 h with 10 ng/ml IL-1 or left untreated. DCP1a 
and Edc4 localization was analyzed by double immune fluorescence analysis. The minus sign indicates samples from untreated cells. Bar, 10 µM. (F) Cells 
were treated as in D for the indicated times with 10 ng/ml IL-1, and DCP1a and p65 proteins were analyzed in cytosolic and nuclear cell extracts by 
Western blotting. Black lines indicate that intervening lanes have been spliced out. mIgG, murine IgG; rIgG, rabbit IgG; IB, immunoblot; wt, wild type.JCB • VOLUME 194 • NUMBER 4 • 2011   592
Callebaut, 2002). Recently, DCP1a was also found to inter-
act  with  PNRC2  (proline-rich  nuclear  receptor  coregula-
tory protein 2) in P bodies as part of the nonsense-mediated   
decay  pathway  (Cho  et  al.,  2009).  PNRC2  and  its  homo-
logue  PNRC1  also  act  as  transcriptional  coactivators  of  vari-
ous  steroid  receptors  (Zhou  et  al.,  2000;  Zhou  and  Chen, 
2001). Neither SMADs nor PNRC1/2 has so far been im-
plicated in IL-1–mediated nuclear signaling (Weber et al., 
2010). Most likely, therefore, DCP1a has separate roles in   
TGF-, nuclear hormone, and IL-1 signaling that warrant 
further investigations.
In summary, our study reveals two hitherto unrecog-
nized aspects of DCP1a regulation: first, phosphorylation-
mediated  control  of  subcellular  localization  and  second, 
nuclear suppression of NF-B target genes. Signal-regulated 
localization  of  DCP1a  has  evolved  late,  as  JNKs  are  not 
found in lower eukaryotes, such as yeast, and the sequence 
motif PLSP is only found in primates and rodents (Fig. 9). 
This pathway may specifically serve to direct DCP1a to tran-
scriptional and posttranscriptional functions in response to 
physiological stimuli.
Materials and methods
Cells
HEK293 cells stably expressing the IL-1 receptor (HEK293IL-1R; Thiefes   
et al., 2006), JNK1/2, and p38 MAPK-deficient MEF lines have been previ-
ously described (Thiefes et al., 2005; Wolter et al., 2008) and were gifts 
from E. Wagner (Cancer Cell Biology Program, Spanish National Cancer 
Center, Madrid, Spain) and A. Nebreda (Institute for Research in Biomedi-
cine Barcelona, Barcelona, Spain), respectively. Cells were cultured in Dul-
becco’s modified Eagle’s medium complemented with 10% fetal calf serum, 
2 mM l-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin.
Materials
Antibodies against the following proteins or peptides were used: actin 
(JLA20; EMD) and DCP1a (H00055802-M06; Abnova); MYC (9E10), GFP 
(clones 7.1 and 13.1), and HA (12CA5; all obtained from Roche); P(T180/
Y182)-p38 MAPK (36–850; Invitrogen); TAB1 (sc-13956), TAK1 (sc-7162), 
JNK (D-2 and sc-7345), tubulin (TU-02; sc-8035), Xrn1 (C-1; sc-165985), 
and p65 NF-B (C-20; sc-372; all obtained from Santa Cruz Biotechnology, 
Inc.); P(Ser73)-c-Jun (9164), JNK (9252), P(T183/Y185)-JNK (9251), and 
Edc4 (25485; all obtained from Cell Signaling Technology); and rabbit 
and mouse IgG (Santa Cruz Biotechnology, Inc.). Other antibodies were as 
follows: long JNK2 (SAK9 raised against DSSLDASTGPLEGCR; human with   
C-terminal 15 residues), short JNK3 (SAK10 raised against GVVKGQP-
SPSAQVQQ; human with C-terminal 15 residues), JNK (Ab681; chicken 
antibody  raised  against  GST-JNK3),  and  p38  MAPK  (SAK7  raised 
against  ISFVPPPLDQEEMES;  rat  p38  with  C-terminal  15  residues). 
All were gifts from J. Saklatvala (The Kennedy Institute of Rheumatology,   
Imperial  College  London,  London,  England,  UK;  Krause  et  al.,  1998; 
Finch et al., 2001). Purified polyclonal antibodies that recognize specific 
phosphorylation at S315 in human DCP1a were raised against the fol-
lowing  peptides:  TYTIPL-(phospho)S-PVLSPT  (Eurogentec)  or  NEKHAPTY-
TIPL-(phospho)-S-PVLSPTLPAEAPTAQV  (PickCell  Laboratories).  Polyclonal 
rabbit  antibodies  against  GFP  or  GAL4  were  gifts  from  E.  Izaurralde 
(Max Planck Institute for Developmental Biology, Tübingen, Germany) or   
L. Schmitz (Justus Liebig University Giessen, Giessen, Germany), respec-
tively.  HRP-coupled  secondary  antibodies  were  goat  anti–mouse  IgG 
and goat anti–rabbit IgG obtained from Dako, rabbit anti–chicken IgG   
(A-9046) obtained from Sigma-Aldrich, and TrueBlot anti–mouse or –rabbit 
IgG obtained from eBioscience.
The expression plasmid for GST–c-Jun (amino acids 1–135) was a 
gift from J.R. Woodgett (Samuel Lunenfeld Research Institute, Mount Sinai 
Hospital, Toronto, Ontario, Canada). Expression of GST fusion proteins 
was induced in the Escherichia coli BL21 strain by 0.5–1 mM IPTG for 4 h   
at 37°C, and proteins were purified from bacterial extracts by glutathione– 
Sepharose  beads,  eluted  with  20  mM  glutathione,  dialysed  against   
Sorbitol and anisomycin caused sustained JNK activation as 
well as sustained DCP1a phosphorylation and disintegration of 
P bodies as judged by the cytosolic redistribution of Edc4 and 
Xrn1.  This  mechanism  may  be  operative  for  those  mRNAs 
whose decay is supposed to be accelerated in the cytoplasmic 
pool of nontranslated mRNAs during stress.
In contrast, transient JNK activation in response to IL-1 
was paralleled by enhanced DCP1a phosphorylation and by 
an increase in Edc4- and Xrn1-positive P bodies. This mecha-
nism  may  serve  to  selectively  sequester  mRNAs  from  the 
RNA decay machinery in a gene-specific manner. We propose 
that some IL-1–induced mRNAs are directed to P bodies to 
become rapidly degraded after initial induction as exempli-
fied for IB. Others are retained in the cytoplasm to delay 
P body–mediated decay. These mRNAs are more stable and 
are expressed and translated for longer times as exemplified 
for IL-8. Support of this interpretation is derived from the ob-
servation that a phosphomimetic mutant of DCP1a stabilized 
IL-8 mRNA but not IB mRNA. These data point to a novel 
role of P bodies in selective termination of proinflammatory 
cytokine action. However, full proof of this hypothesis will 
require the development of methods to separately determine 
mRNA species and decapping activities in P bodies and within 
the cytoplasm, respectively.
Microarray analyses revealed that mutants of DCP1a that 
interfere  with  phosphorylation-mediated  shuttling  (S315D 
and S315A) or with its trimerization (515–582) exerted a 
strong dominant-negative effect on virtually all IL-1 response 
genes (Fig. S4). The suppression of steady-state mRNA lev-
els of all of these genes and the inhibition of an IL-8 promoter 
construct suggested that DCP1a played an unexpected role   
in transcriptional regulation of IL-1 response genes. We found 
that a minor fraction of DCP1a was localized in the nucleus 
(Fig. 8, E and F), whereas other decapping proteins, such 
as Edc4, were localized exclusively in the cytoplasm or in   
P bodies (Fig. 8 E). DCP1a interacted with p65 NF-B and 
suppressed  p65-mediated  transcription  (Fig.  8,  B–D).  All 
these results point to DCP1a as a novel multifunctional regu-
lator of gene expression in cytokine signaling.
This interpretation is in line with previous observations 
suggesting that DCP1a can have both transcriptional and post-
transcriptional functions. In yeast, DCP1a was identified as a 
regulatory subunit of the decapping enzyme DCP2 (Beelman   
et al., 1996; Dunckley and Parker, 1999). In metazoan cells, it 
requires more complex interactions with other proteins (Lsm1-7, 
Edc3, Edc4 [hedls], and DDX6/RCK) to enhance decapping 
(Fenger-Grøn et al., 2005; Bail and Kiledjian, 2006; Franks and 
Lykke-Andersen, 2008; Buchan and Parker, 2009). The phos-
phorylation site S315 is not part of a region that has been previ-
ously found to participate in decapping or in binding to DCP2 
or  to  other  subunits  of  the  decapping  complex  (Franks  and 
Lykke-Andersen,  2008).  Accordingly,  mutation  of  S315  did   
not affect decapping activity associated with DCP1a immuno-
precipitates (Fig. 5).
In  an  independent  study,  DCP1a  was  identified  as  a 
SMAD4-interacting protein (called SMIF) that acted as a tran-
scriptional coactivator in the TGF- pathway (Bai et al., 2002; 593 JNK interacts with and phosphorylates DCP1a • Rzeczkowski et al.
pEGFP-DCP1aS422A, pEGFP-DCP1aS522/523/525A, pEGFP-DCP1aT531A, pDEST15-
DCP1a,  pDEST15-DCP1aS315A,  pFA-DCP1aS315A,  pFA-DCP1aS315D,  and 
pFA-DCP1515–582.
Unless indicated otherwise, cells were seeded at 2–5 × 10
5 for   
6-well plates, 4.5 × 10
6 for T75 (75 cm
2) flasks, and 9.8 × 10
6 for T175 
(175 cm
2) flasks and transfected with 5–7.5, 20–40, or 50–100 µg plas-
mid  DNA,  respectively.  Transfections  were  performed  with  the  CaPO4 
method as previously described (Holtmann et al., 2001). Stable cell lines 
of HEK293IL-1R cells were generated by transfecting 5 µg pEGFP-DCP1a 
constructs (Fig. 5) and 1 µg pBSPACP. Cells were selected and main-
tained in1 µg/ml puromycin. 50–65% of all cells in stably transfected cell 
pools expressed GFP-DCP1a constructs.
Cell  lysis,  luciferase,  and  -galactosidase  assays  for  determina-
tion of reporter gene activities have been previously described (Holtmann   
et al., 2001; Thiefes et al., 2005). In brief, cells were lysed in ice-cold 
potassium phosphate buffer (8.5 mM KH2PO4, 91.5 mM K2HPO4, pH 7.8, 
0.2% Triton X-100, 1 µg/ml pepstatin, 10 µg/ml leupeptin, and 1 mM 
PMSF) for 15 min on ice. Lysates were cleared for 15 min at 10,000 g at 
4°C. 20 µl lysate was mixed with 100 µl luciferase buffer (20 mM tricin,   
1.07 mM (MgCO3)4Mg(OH)2 × 5H2O, 2.67 mM MgSO4, 33.3 mM DTT, 
0.53 mM ATP, 30 mg coenzyme A, and 472 µM d-luciferine), and chemi-
luminescence was recorded for 10 s in a 96-well luminometer (Fluoroscan 
Ascent FL; Laboratory systems). -Galactosidase activity was measured 
with reagents from Takara Bio Inc.
Immunostaining and fluorescence microscopy
HEK293IL-1R cells were seeded for 24 h in µ-Slides VI (ibidi). After wash-
ing, cells were fixed with 4% paraformaldehyde in HBSS (PAA Laboratories) 
for 5 min, blocked with 10% normal donkey serum (Dianova) for 30 min,   
and incubated with primary and secondary antibodies diluted in HBSS 
20 mM Tris, pH 7.4, 100 mM NaCl, and 2 mM DTT, and stored at 220°C 
in 50% glycerol according to standard methods.
Protein A– or G–Sepharose were purchased from GE Healthcare. 
Human recombinant IL-1 was a gift from J. Saklatvala and was expressed 
in E. Coli and purified by sequential column chromatography as described 
previously (Krause et al., 1998; Wolter et al., 2008). SP600125 and 5Z-7- 
oxozeaenol were obtained from Tocris Bioscience, and SB203580 was 
purchased from EMD. Anisomycin, sorbitol, and all other reagents were 
purchased from Sigma-Aldrich or Thermo Fisher Scientific and were of ana-
lytical grade or better.
Plasmids, transfections, stable cell lines, and reporter gene assays
The following plasmids have been described previously: pUHC13-3 IL-8   
promoter  luciferase  (Holtmann  et  al.,  1999),  peVHA-JNK2,  peVHA-
JNK2K55R (Krause et al., 1998), pQBI-MEKK1998–2743-BFP (Thiefes et al., 
2006), pGAL4-p65, pBSPACP (Thiefes et al., 2005), and pEGFP-p65 
(Buss et al., 2004). pEGFP-DCP1a, pEGFP-DCP2, and pEGFP-DCP1515–582 
were cloned by RT-PCR, pCDNA3.1-TAK1kdTAB1ad was obtained from   
H. Sakurai (Institute of Natural Medicine, University of Toyama, Sugitani, 
Toyama,  Japan),  pFA-DCP1a  and  pFA-DCP1A125–377  were  obtained 
from J. Duyster and S. Kuhn (Laboratory of Leukemogenesis, Technical 
University  of  Munich,  Munich,  Germany;  Bai  et  al.,  2002),  pEBB-HA-
p65  was  obtained  from  L.  Schmitz,  pSV–-galactosidase  and  pGL2-
control were purchased from Promega, pEGFP-C1 was purchased from 
Takara  Bio  Inc.,  and  pFC2–DNA-binding  domain  and  pFR-luciferase 
were purchased from Agilent Technologies. The following plasmids were   
constructed  by  standard  cloning  techniques:  pEGFP-DCP1aS60/62A, 
pEGFP-DCP1aS140/142A,  pEGFP-DCP1aS179/180A,  pEGFP-DCP1aT289/290A, 
pEGFP-DCP1aS315A,  pEGFP-DCP1aS315D,  pEGFP-DCP1aS319A,  pEGFP-
DCP1aS334A, pEGFP-DCP1aT347/348A, pEGFP-DCP1aS353A, pEGFP-DCP1aT401A, 
Figure 9.  Scheme of DCP1a as a multifunctional downstream effector of the JNK pathway. In addition to its known role in AP-1–mediated transcriptional 
control through the phosphorylation of c-Jun, JNK binds to and colocalizes with DCP1a. JNK activation results in phosphorylation-dependent shuttling of 
DCP1a between P bodies and the cytoplasm to modulate the translational output of stress- or inflammation-induced genes. DCP1a also affects IL-1–induced 
mRNA transcription by affecting p65 NF-B–mediated gene expression. The gray shading indicates phosphorylated JNK substrates. (inset) Conservation of 
the JNK phosphorylation motif surrounding S315 (shaded in gray) of human DCP1a. For details see Discussion. P, phosphorylated.JCB • VOLUME 194 • NUMBER 4 • 2011   594
25% glycerol, 0.3 mM Na3VO4, 20 mM -glycerophosphate, 200 µM 
leupeptin, 10 µM E64, 300 µM PMSF, 0.5 µg/ml pepstatin, 5 mM DTT, 
and 400 nM okadaic acid). After 1 h on ice, nuclear extracts were cleared 
at 10,000 g for 5 min at 4°C, and supernatants were collected. Protein 
concentration of cell extracts was determined by the Bradford method, and 
samples were stored at 280°C.
Soluble (S2) and particular (P2) fractions (Fig. 3 D) were prepared 
as previously described (Teixeira et al., 2005). In brief, cells from one 
T175 (175 cm
2) flask were washed in ice-cold PBS, pelleted, and lysed 
in 1 ml lysis buffer (50 mM Tris, pH 7.6, 50 mM NaCl, 5 mM MgCl2, 
0.1% NP-40, 1 mM -mercaptoethanol, proteinase inhibitor mix [Roche], 
0.4 U/µl RNase inhibitor [RiboLock; Fermentas], and 1 µM microcystin). 
Samples were kept for 15 min on ice, vortexed three times, and then 
centrifuged for 2 min at 2,000 g at 4°C. The supernatant was recov-
ered and centrifuged for 10 min at 10,000 g at 4°C. The supernatant 
(S2) was taken as cytosolic extract, and the pellet (P2) was taken as a 
P body–enriched particular fraction. P2 was diluted in 1 ml immuno-
precipitation buffer (50 mM Hepes, pH 7.4, 50 mM NaCl, 1% Tween 
20, 2.5 mM EGTA, 1 mM EDTA, 10 mM -glycerophosphate, 0.1 mM 
Na3VO4, 1 mM PMSF, protease inhibitor mix, 1 mM DTT, and 1 µM 
microcystin) and sonified three times for 20 s on ice. 370 µg S2 proteins 
were adjusted to 150 µl with lysis buffer. Both S2 and P2 containing 
equal amounts of proteins were diluted into 500 µl immunoprecipitation 
buffer and were precleared with 15 µl TrueBlot anti–rabbit IgG immuno-
precipitation  beads  (00–8800).  The  supernatant  was  incubated  with   
1 µg rabbit IgG or with anti-JNK antibodies (2.5 µl SAK9 + 2.5 µl SAK10) 
precoupled to 15 µl IgG beads. Samples were end-to-end rotated over-
night at 4°C, and beads were washed three times in immunoprecipita-
tion buffer including 450 mM NaCl. Proteins were eluted by boiling in 
SDS-PAGE sample buffer, separated by SDS-PAGE, immunoblotted, and 
detected by the indicated primary antibodies followed by TrueBlot HRP- 
conjugated anti–rabbit IgG (18-8816) or anti–mouse IgG (18-8817).
Coimmunoprecipitations
For  coimmunoprecipitations  of  overexpressed  GFP-p65,  HA-p65,  and 
GFP-DCP1 (Fig. 8 D), cells were lysed in 50 mM Hepes, pH 7.4, 50 mM 
NaCl, 1% Tween 20, 2.5 mM EGTA, 1 mM EDTA, 1 mM NaF, 10 mM 
-glycerophosphate, 0.1 mM Na3VO4, 1 mM PMSF, protease inhibitor 
mix, and 1 mM DTT, sonified five times for 30 s on ice in a sonicator   
(Biorupter; Diagenode) at the high setting with 30-s intervals, and centri-
fuged at 100,000 g for 20 min at 4°C. 1 mg of the supernatant in 400 µl 
lysis buffer was precleared with 25 µl TrueBlot anti–rabbit or anti–mouse 
Ig  immunoprecipitation  beads  (00-8811).  Then,  1  µg  anti-DCP1,  anti-
p65, or IgG antibodies precoupled overnight to 15 µl TrueBlot Ig immuno-
precipitation beads was added for 4 h at 4°C. Thereafter, beads were 
washed three times in 1 ml lysis buffer. Proteins were eluted by boiling   
in SDS-PAGE sample buffer, and immunoblotted proteins were detected 
by  the  indicated  primary  antibodies  and  TrueBlot  HRP-conjugated   
anti-IgG antibodies.
Immunoblotting and ELISA
Immunoblotting  was  performed  essentially  as  previously  described   
(Hoffmann et al., 2005). Proteins were separated on 6–10% SDS-PAGE 
and electrophoretically transferred to polyvinylidene fluoride membranes 
(Millipore). After blocking with 2 or 5% dried milk in Tris-HCl–buffered 
saline/0.05%  Tween  (TBST)  for  1  h,  membranes  were  incubated  for   
12–24 h with primary antibodies, washed in TBST, and incubated for 
1–2 h with the peroxidase-coupled secondary antibody. Proteins were 
detected by using ECL systems from Thermo Fisher Scientific, Millipore, 
or GE Healthcare. IL-8 secretion was measured by the IL-8 ELISA develop-
ment kit (DuoSet; R&D Systems).
RT-PCR
1  µg  total  RNA  was  prepared  by  a  minispin  kit  (NucleoSpin  RNA  II;   
Macherey-Nagel) and transcribed into cDNA using Moloney murine leuke-
mia virus reverse transcription (Fermentas) in a total volume of 20 µl. 2 µl of 
this reaction mixture was used to amplify cDNAs using assays on demand   
(Applied Biosystems) for IL-8 (Hs00174103_m1), IB (Hs00153283_m1), 
and  -actin  (Hs99999903_m1)  on  a  real-time  PCR  instrument  (ABI   
7500). The cycle threshold (ct) value for each individual PCR product was 
calculated by the instrument’s software, and ct values obtained for IL-8 or 
IB were normalized by subtracting the ct values obtained for -actin. The 
resulting ct values were then used to calculate relative changes of mRNA 
expression as ratio (R) of mRNA expression of stimulated/unstimulated 
cells according to the equation R = 2
2(ct[stimulated] 2 ct[unstimulated]).
containing 0.1% saponin (Sigma-Aldrich) for 2 h at room temperature. Cy3- 
conjugated (1:200; Millipore) and FITC-conjugated (1:100; Sigma-Aldrich) 
secondary antibodies were used. For controls, primary antibodies were 
omitted. Nuclei were stained with Hoechst 33342 (Invitrogen).
Image acquisition and processing
Immunofluorescence analyses were performed on an inverse microscope 
(DMIRE2; Leica) equipped with a monochrome digital camera (DFX350 
FX R2; Leica). Fluorescence image acquisition was performed at room 
temperature using a 40-fold objective lens (40×/0.6 NA dry; HCX PL 
Fluotar; Leica) and appropriate filter cubes (DAPI: excitation 359 nm and 
emission 461 nm; FITC: excitation 490 nm and emission 520 nm; Cy3: 
excitation 550 nm and emission 570 nm; GFP: excitation 489 nm and 
emission 508 nm). Standard image processing was performed with the 
FW4000 software (version 1.2.1; Leica) using contrast, deconvolution, 
and merge applications (DAPI:  reduction = 0.90, 2D deconvolution 
[haze  removal  70%,  smoothing  4,  and  spot  removal  60],  and  70% 
merged; FITC:  reduction = 0.70, local contrast enhancement = 30%, and 
90% merged; Cy3:  reduction = 0.90, local contrast enhancement = 30%, 
and 100% merged). In Fig.6 C (bottom), additional image processing 
was preformed by using the Deblur software (version 2.3.2; Leica) with 
25%  background  equalization  and  removing  of  negative  intensities.   
Subsequently, 2D blind deconvolution was performed with the following 
settings:  all  channels,  low  noise  smoothing,  20  total  iterations,  point 
spread function correction factor 2, and super resolution factor 1.
In vitro kinase assays
For immune complex protein kinase assays, whole-cell extracts (0.85– 
2 mg protein) were diluted in 500 µl ice-cold immunoprecipitation buffer 
(20 mM Tris-HCl, pH 7.4, 154 mM NaCl, 50 mM NaF, 1 mM Na3VO4, 
1% Triton X-100, and 2 mM DTT). Samples were incubated for 2–3 h 
with 2–4 µl antibodies against JNK followed by the addition of 30 µl 
protein A– or protein G–Sepharose beads and incubation for 1–2 h at 
4°C. Beads were spun down, washed 3× in 1 ml immunoprecipitation 
buffer, and resuspended in 10 µl of the same buffer. Then, 2–3 µg re-
combinant protein substrates (GST, GST–c-Jun1–135, or GST–DCP1-) in 
10 µl H2O and 10 µl kinase buffer (150 mM Tris-HCl, pH 7.4, 30 mM 
MgCl2, 15 µM ATP, and 8 µCi -[
32P]ATP) was added. After 30 min 
at room temperature, the SDS sample buffer was added, and proteins 
were eluted from the beads by boiling for 5 min. After centrifugation at 
16,000 g for 5 min, supernatants of both types of kinase assays were 
separated by 7.5–10% SDS-PAGE. Phosphorylated proteins were visual-
ized by autoradiography.
For nonradioactive immune complex protein kinase assays (Fig. 2 B),   
whole-cell extracts from separate cell cultures transfected with plasmids 
encoding protein kinases or substrates were prepared as described in the 
previous paragraph. 4–5 mg lysate proteins were incubated with anti-
bodies against JNK (SAK9; 3 µl) or GFP (anti-GFP; 2 µg) precoupled to   
30  µl  protein  G–Sepharose.  Immunoprecipitations  were  performed  in   
500 µl immunoprecipitation buffer for 2.5 h at 4°C. Immunopurified kinase 
and substrate samples were washed twice with 1 ml immunoprecipitation   
buffer, combined, washed again, and resuspended in 20 µl immunoprecipita-
tion buffer. 20 µl H2O and 20 µl kinase buffer (150 mM Tris-HCl, pH 7.4, 
30 mM MgCl2, and 135 µM ATP) were added. After 30 min at room 
temperature, proteins were eluted from the beads by boiling for 10 min 
as described in the previous paragraph. Proteins were separated on SDS-
PAGE and detected by immunoblotting.
Cell lysis and immunoprecipitations from soluble and particular fractions
For whole-cell extracts, cells were lysed in Triton X-100 cell lysis buffer   
(10 mM Tris, pH 7.05, 30 mM NaPPi, 50 mM NaCl, 1% Triton X-100, 
2 mM Na3VO4, 50 mM NaF, 20 mM -glycerophosphate, and freshly 
added 0.5 mM PMSF, 0.5 µg/ml leupeptin, 0.5 µg/ml pepstatin, and   
1 µg/ml microcystin) as previously described (Holtmann et al., 1999). Cell 
lysates were subjected to SDS-PAGE on 6–10% gels, and immunoblotting 
was performed as described in the Immunoblotting and ELISA section.
Nuclear and cytosolic extracts were prepared as described previ-
ously (Holtmann et al., 1999). In brief, cells were suspended and pelleted 
in buffer A (10 mM Hepes, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.3 mM 
Na3VO4, freshly added 200 µM leupeptin, 10 µM E64, 300 µM PMSF, 
0.5 µg/ml pepstatin, 5 mM DTT, 400 nM okadaic acid, and 20 mM 
-glycerophosphate). The pellet was resuspended in buffer A containing 
0.1% NP-40. After centrifugation at 10,000 g for 5 min at 4°C, superna-
tants were taken as cytosolic extracts. Pellets were resuspended in buffer B 
(20 mM Hepes, pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 595 JNK interacts with and phosphorylates DCP1a • Rzeczkowski et al.
available at http://www.jcb.org/cgi/content/full/jcb.201006089/DC1. 
Multicolor images shown in Fig. 1 A, Fig. 4 B, and Fig. 6 C can be viewed 
via the JCB DataViewer at http://jcb-dataviewer.rupress.org/.
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Decapping assays
Decapping  assays  were  performed  essentially  as  previous  described  in 
Tritschler et al. (2009). In brief, a 176-bp luciferase cDNA template was am-
plified by PCR from pGL2-control (Promega) using the primers sense, 5-GCGT-
AATACGACTCACTATAGGGAGAATGGAACCGCTGGAGAGCA-3, 
and antisense, 5-TCTGTGATTTGTATTCAGCC-3. mRNA was transcribed 
in vitro using the MEGAscript T7 kit (Invitrogen), purified by the mirVana 
kit (Invitrogen) using the total RNA protocol, and eluted in 100 µl H2O.   
2 µg mRNA was heated at 65°C for 10 min and then capped in a reaction 
mixture containing 2 µl of 10× ScriptCap capping buffer, 2 µl (20 µCi)   
-[
32P]GTP, 1 µl of 2-mM S-adenosylmethionine, 0.5 µl ScriptGuard RNase 
inhibitor (40 U/µl), and 1 µl (10 U) script capping enzyme in a total volume 
of 20 µl using the capping system kit (ScriptCap m7G; Epicentre). After   
60 min at 37°C, mRNA was purified by the mirVana kit as described previ-
ously in this paper. For the experiment shown in Fig. 5, one T175 (175 cm
2) 
flask of HEK293IL-1R cells was transfected with 50 µg GFP-DCP2 or GFP-
DCP1a expression vectors and 30 µg pCDNA3 using the calcium phosphate 
method. After 24 h, cells were lysed in 1 ml NET buffer (50 mM Tris, pH 
7.5, 150 mM NaCl, 1 mM EDTA, 0.1% Triton X-100, and 10% glycerol 
plus freshly added protease inhibitors). After 15 min on ice, lysates were 
cleared at 18,000 g for 15 min at 4°C. GFP-tagged proteins were immuno-
precipitated from 3 mg protein in 1 ml NET buffer for 2 h at 4°C using 1 µg 
anti-GFP antibodies precoupled to 25 µl protein G–Sepharose slurry. Beads 
were washed 3× in 1 ml NET buffer, 1× in 1 ml NET buffer 2 (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, and 0.05% Triton X-100), and 1× in 0.975 ml 
decapping buffer (50 mM, Tris-HCl, pH 7.9, 30 mM ammonium sulfate, and 
1 mM MgCl2). One fourth of the material was used for Western blotting. The 
remaining three fourths of the immunoprecipitate was resuspended in 1 vol 
decapping buffer including 0.1 mM cap structure analogue G(5)ppp(5)G 
RNA (New England Biolabs, Inc.) and 0.4 U/µl RNase inhibitor. 5 µl of this 
reaction was mixed with 50 ng 
32P-labeled luciferase mRNA in a total vol-
ume of 10 µl decapping buffer and rotated horizontally at 1,400 rpm. After 
30 min at 30°C, the reaction was stopped by addition of 50 mM EDTA, and 
5 µl was separated on polyethylenimine thin layer chromatography plates 
(Merck) using 0.75 M LiCl as a solvent. 25 µg m
7GDP and m
7GTP (Sigma-
Aldrich) was used as a standard.
Microarray-based mRNA expression analysis
The Whole Human Genome Oligo Microarray (Agilent Technologies) used 
in this study contains 45,015 oligonucleotide probes covering the entire 
human transcriptome. Synthesis of Cy3-labeled cRNA was performed with 
the Quick Amp Labeling kit, one color (Agilent Technologies) according to 
the manufacturer’s recommendations. cRNA fragmentation, hybridization, 
and washing steps were also carried out exactly as recommended for the 
One-Color  Microarray-Based  Gene  Expression  Analysis  Protocol  V5.7 
(Agilent  Technologies).  Slides  were  scanned  on  a  microarray  scanner 
(pixel  resolution  of  5  µm  and  bit  depth  of  20;  Microarray  Scanner 
G2565CA; Agilent Technologies). Data extraction was performed with the 
Feature Extraction Software V10.7.3.1 by using the recommended default 
extraction protocol file GE1_107_Sep09.xml.
Processed intensity values of the green channel (gProcessedSignal 
or gPS) were normalized by global linear scaling: all gPS values of one 
sample were multiplied by an array-specific scaling factor. This scaling fac-
tor was calculated by dividing a reference 75th percentile value (set as 
1,500 for the whole series) by the 75th percentile value of the particular 
microarray (Array i in the formula shown in this paragraph). Accordingly, 
normalized gPS values for all samples (microarray datasets) were calcu-
lated by the following formula: normalized gPSArray i = gPSArray i × (75th Per-
centileReference Array/75th PercentileArray i).
A lower intensity threshold was defined as 1% of the reference 75th 
Percentile value (threshold = 15). All of those normalized gPS values that 
fell below this intensity border were substituted by the respective surrogate 
value of 15. Calculation of ratio values of relative gene expression and 
data filtering was performed using Excel macros (Microsoft).
Statistics
Statistics were calculated by the Mann–Whitney rank test or paired t test 
using Sigma Plot12 (Systat Software, Inc.).
Online supplemental material
Fig. S1 shows mapping of JNK-dependent phosphorylation sites in DCP1a. 
Fig. S2 shows microscopic analysis of P body–enriched (P2) fractions. 
Fig.  S3  shows  DCP1a  phosphorylation  and  P  body  formation  in  JNK- 
deficient MEFs. Fig. S4 shows impaired IL-1 response in HEK293IL-1R cells 
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